Radiosensitization in prostate cancer: Mechanisms and targets

BMC Urology

Volumn 13, Issue , 2013, Pages

  Palacios, Diego A ^a   Miyake, Makito ^a   Rosser, Charles J ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

Cancer; Prostate; Radiation; Radiosensitizer

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; 4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; ADAM PROTEIN; ADAM9 PROTEIN; ADENOVIRUS VECTOR; ATM PROTEIN; BEVACIZUMAB; CELECOXIB; CYCLOOXYGENASE 2; GEFITINIB; GENISTEIN; MK 1775; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE METHYL ESTER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OBLIMERSEN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SOMATOMEDIN C RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN; VORINOSTAT;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; COMPTON EFFECT; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; FOLLOW UP; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTENSITY MODULATED RADIATION THERAPY; IONIZING RADIATION; MITOSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CLINICAL TRIALS AS TOPIC; DNA DAMAGE; DRUG DELIVERY SYSTEMS; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 84872815960     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-13-4     Document Type: Review

References (171)

1. Cancer statistics 2012. Siegel R, Naishadham D, Jemal A, CA Cancer J Clin 2012 62 10 29 10.3322/caac.20138 22237781
2. SEER cancer statistics review 1975-2008. Lifetime risk (percent) of being diagnosed with cancer by site and race/ethnicity: males, 17 SEER areas, 2006-2008 (Table 1.15) And females, 17 SEER areas, 2006-2008 (Table 1.16). National Cancer Institute, 2011 Accessed at http://seer.cancer.gov/csr/1975- 2008/results-merged/topic-lifetime-risk-diagnosis.pdf on August 28, 2012
3. Prostate cancer incidence and mortality rates among white and black men. Merrill RM, Brawley OW, Epidemiology 1997 8 126 131 10.1097/00001648-199703000- 00001 9229202
4. Prostate brachytherapy: increasing demand for the procedure despite the lack of standardized quality assurance and long term outcome data. D'Amico AV, Vogelzang NJ, Cancer 1999 86 9 1632 1634 10.1002/(SICI)1097-0142(19991101)86: 9<1632::AID-CNCR2>3.0.CO;2-5 10547533
5. Intensity-modulated radiation therapy for prostate cancer. Zelefsky MJ, Fuks Z, Leibel SA, Semin Radiat Oncol 2002 12 3 229 237 Review 10.1053/srao.2002.00000 12118388
6. Brachytherapy versus radical prostatectomy. Ravery V, BJU Int 2001 87 141 143 11167631
7. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, et al. Int J Radat Oncol Biol Phys 1995 32 3 12 10.1016/0360-3016(95)00063-5
8. Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma. Kuban DA, El-Mahdi AM, Schellhammer PF, Urol 1987 30 420 426 10.1016/0090-4295(87)90372-4 3118547
9. Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation. Zagars GK, von Eschenbach AC, Johnson DE, Oswald MJ, Cancer 1987 60 1489 1499 10.1002/1097-0142(19871001)60:7<1489:: AID-CNCR2820600715>3.0.CO;2-9 3113715
10. Conventional vs conformal radiotherapy for prostate cancer. Preliminary results of Dosimetry and acute toxicity. Pollack A, Zagars GK, Starkschall G, Childress CH, Kopplin S, Boyer AL, et al. Int J Radiat Oncol Biol Phys 1996 34 555 564 10.1016/0360-3016(95)02103-5 8621278
11. Prostate cancer. Radiation therapy for localized disease. Bagshaw MA, Kaplan ID, Cox RC, Cancer 1993 47 929 952
12. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with78 Gy for prostate cancer. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I, JCO 2000 18 3904 3911
13. Smith RP, McKenna WG, The Basics of Radiation Therapy 3 Clinical Oncology. 2004
14. Perez CA, Brady L, Principles and practice of radiation oncology Philadelphia: Lippincott Williams & Wilkins 3 1997
15. The physicist in cancer treatment and detection. Johns HE, Int J Radiat Oncol Biol Phys 1981 7 801 808 10.1016/0360-3016(81)90477-6 6793544
16. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Radford IR, Int J Radiat Biol Relat Stud Phys Chem Med 1986 49 611 620 3485603
17. Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Nunez MI, McMillan TJ, Valenzuela MT, de Almodovar JM R, Pedraza V, Radiother Oncol 1996 39 155 165 10.1016/0167-8140(96)01732-X 8735483
18. Introductory review: involvement of ADP-ribosylation in cellular recovery from some forms of DNA damage. Lunec J, Br J Cancer 1984 6 13 18
19. Correlation between cellular radiosensitivity and non-repaired double-strand breaks studied in nine mammalian cell lines. Dikomey E, Dahm-Daphi J, Brammer I, Martensen R, Kaina B, Int J Radiat Biol 1998 73 269 278 10.1080/095530098142365 9525255
20. AX-ray sensitive mutants of Chinese hamster ovary cells defective in double-strand break rejoining. Kemp LM, Sedgwick SG, Jeggo P, Mutat Res 1984 132 189 196 10.1016/0167-8817(84)90037-3 6513971
21. The relative radiosensitivity of the nucleus and cytoplasm of Chinese hamster fibroblasts. Munro TR, Radiat Res 1970 42 451 470 10.2307/3572962 5463516
22. The relative radiosensitivity of the nucleus and cytoplasm of Chinese hamster fibroblasts. Munro TR, Exp Cell Res 1960 20 613 10.1016/0014-4827(60) 90138-5 13772379
23. Radionuclide toxicity in cultured mammalian cells: Elucidation of the primary site of radiation damage. Walters R, Hofer K, Harris C, Ann Top Radiat Res Q 1977 12 389
24. Constraints on energy deposition and target size of multiply damaged sites associated with DNA double-strand breaks. Brenner DJ, Ward JF, Int J Radiat Biol 1992 61 737 748 10.1080/09553009214551591 1351522
25. A short history of the radiation chemistry of water. Jonah CD, Radiat Res 1995 144 141 147 10.2307/3579253 7480640
26. The time interval after pulsed irradiation within which injury in bacteria can be modified by dissolved oxygen. I. A Search for an effect of oxygen 0.02 seconds after pulsed irradiation. Howard-Flanders P, Moore D, Radiat Res 1958 9 422 437 10.2307/3570768 13591515
27. Biochemistry of DNA lesions. Ward JF, Radiat Res 1985 8 103 111
28. Physics of radiation action: Microscopic features that determine biological consequences. Goodhead D, 10th International Congress of Radiation Research Wurzburg, Germany: Congress Lectures, Hagen U, Jung P, Streffer C, 1995 43
29. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Molls M, Stadler P, Becker A, Feldmann HJ, Dunst J, Strahlenther Onkol 1998 174 13 16 9879341
30. Steel G, Adama C, Peckham M, The Biological Basis of Radiotherapy Amsterdam: Elsevier Science 1983
31. Historic milestones in radiobiology and radiation therapy. Kaplan HS, Semin Oncol 1979 6 479 489 119321
32. Radiation and the cell cycle, revisited. Wilson GD, Cancer Metastasis Rev 2004 23 209 225 15197324
33. Fission yeast rad17: A homologue of budding yeast RAD24 that shares regions of sequence similarity with DNA polymerase accessory proteins. Griffiths DJ, Barbet NC, McCready S, Lehmann AR, Carr AM, EMBO J 1995 14 5812 5823 8846774
34. The human G2 checkpoint control protein hRAD9 is a nuclear phosphoprotein that forms complexes with hRAD1 and hHUS1. St Onge RP, Udell CM, Casselman R, Davey S, Mol Biol Cell 1999 10 1985 1995 10359610
35. hMre11 and hRad50 nuclear foci are induced during the normal cellular response to DNA double-strand breaks. Maser RS, Monsen KJ, Nelms BE, Petrini JH, Mol Cell Biol 1997 17 6087 6096 9315668
36. Yeast checkpoint genes in DNA damage processing: Implications for repair and arrest. Lydall D, Weinert T, Science 1995 270 1488 1491 10.1126/science.270. 5241.1488 7491494
37. Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells. Tauchi H, Kobayashi J, Morishima K, van Gent DC, Shiraishi T, Verkaik NS, van Heems D, Ito E, Nakamura A, Sonoda E, Takata M, Takeda S, Matsuura S, Komatsu K, Nature 2002 420 93 98 10.1038/nature01125 12422221
38. Substrate specificities and identification of putative substrates of ATM kinase family members. Kim ST, Lim DS, Canman CE, Kastan MB, J Biol Chem 1999 274 37538 37543 10.1074/jbc.274.53.37538 10608806
39. Protein kinase mutants of human ATR increase sensitivity to UV and ionizing radiation and abrogate cell cycle checkpoint control. Wright JA, Keegan KS, Herendeen DR, Bentley NJ, Carr AM, Hoekstra MF, Concannon P, Proc Natl Acad Sci USA 1998 95 7445 7450 10.1073/pnas.95.13.7445 9636169
40. Checkpoint signaling: epigenetic events sound the DNA strand-breaks alarm to the ATM protein kinase. Abraham RT, Bioessays 2003 25 627 630 10.1002/bies.10310 12815717
41. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Bakkenist CJ, Kastan MB, Nature 2003 421 499 506 10.1038/nature01368 12556884
42. Principles of CDK Regulation. Morgan DO, Nature 1995 374 131 134 10.1038/374131a0 7877684
43. Cyclin-dependent protein kinases: Key regulators of the eukaryotic cell cycle. Nigg EA, Bioassays 1995 17 471 480 10.1002/bies.950170603
44. Cell Proliferation and Cancer. Lopez-Saez JF, la TC D, Pincheira J, Gimenez-Martin G, Histol Histopathol 1998 13 1197 1214 9810511
45. What is the restriction point? Zetterberg A, Larsson O, Wiman KG, Curr Opin Cell Biol 1995 7 835 842 10.1016/0955-0674(95)80067-0 8608014
46. X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Terasima T, Tolmach LJ, Science 1963 140 490 492 10.1126/science.140. 3566.490 13980636
47. Variations in several responses of HeLa cells to x-irradiation during the division cycle. Terasima T, Tolmach LJ, Biophys J 1963 3 11 33 10.1016/S0006-3495(63)86801-0 13980635
48. Cyclic x-ray responses in mammalian cells in vitro. Sinclair WK, Radiat Res 1968 33 620 643 10.2307/3572419 4867897
49. The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles. Biade S, Stobbe CC, Chapman JD, Radiat Res 1997 147 416 421 10.2307/3579497 9092920
50. A p53 amino-terminal nuclear export signal inhibited by DNA damage-induced phosphorylation. Zhang Y, Xiong Y, Science 2001 292 1910 1915 10.1126/science.1058637 11397945
51. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C, Genes Dev 2000 14 289 300 10673501
52. CDK inhibitors: Positive and negative regulators of G1-phase progression. Sherr CJ, Roberts JM, Genes Dev 1999 13 1501 1512 10.1101/gad.13.12.1501 10385618
53. The Rb/E2F pathway: expanding roles and emerging paradigms. Harbour JW, Dean DC, Genes Dev 2000 14 2393 2409 10.1101/gad.813200 11018009
54. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Beijersbergen RL, Bernards R, Biochim Biophys Acta 1996 1287 103 120 8672526
55. Rapid destruction of human Cdc25A in response to DNA damage. Mailand N, Falck J, Lukas C, Syljuasen RG, Welcker M, Bartek J, Lukas J, Science 2000 288 1425 1429 10.1126/science.288.5470.1425 10827953
56. A cell kinetic method for the mitotic selection of treated G2 cells. Schneiderman MH, Schneiderman GS, Rusk CM, Cell Tissue Kinet 1983 16 41 49 6825155
57. G2 Cells: progression delay and survival. Schneiderman MH, Schneiderman GS, Radiat Res 1984 98 389 396 10.2307/3576246 6539484
58. DNA damage and repair. Friedberg EC, Nature 2003 421 436 440 10.1038/nature01408 12540918
59. Regulation and mechanisms of mammalian double-strand break repair. Valerie K, Povirk LF, Oncogene 2003 22 5792 5812 10.1038/sj.onc.1206679 12947387
60. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Sarkaria JN, Tibbetts RS, Busby EC, Kennedy AP, Hill DE, Abraham RT, Cancer Res 1998 58 4375 4382 9766667
61. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J, Nature 2001 410 842 847 10.1038/35071124 11298456
62. The cdk-activating kinase (CAK): from yeast to mammals. Kaldis P, Cell Mol Life Sci 1999 55 284 296 10.1007/s000180050290 10188587
63. p107wee1 is a dual-specificity kinase that phosphorylates p34cdc2 on tyrosine 15. Parker LL, Atherton-Fessler S, Piwnica-Worms H, Proc Natl Acad Sci USA 1992 89 2917 2921 10.1073/pnas.89.7.2917 1372994
64. Toward maintaining the genome: DNA damage and replication checkpoints. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA, Annu Rev Genet 2002 36 617 656 10.1146/annurev.genet.36.060402.113540 12429704
65. Partners and pathways repairing a double-strand break. Haber JE, Trends Genet 2000 16 259 264 10.1016/S0168-9525(00)02022-9 10827453
66. Homologous recombination and non-homologous end-joining pathways of DNA double-strand break repair have overlapping roles in the maintenance of chromosomal integrity in vertebrate cells. Takata M, Sasaki MS, Sonoda E, Morrison C, Hashimoto M, Utsumi H, Yamaguchi-Iwai Y, Shinohara A, Takeda S, EMBO J 1998 17 5497 5508 10.1093/emboj/17.18.5497 9736627
67. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM, J Biol Chem 1998 273 5858 5868 10.1074/jbc.273.10.5858 9488723
68. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ, J Biol Chem 2001 276 42462 42467 10.1074/jbc.C100466200 11571274
69. 53BP1, a mediator of the DNA damage checkpoint. Wang B, Matsuoka S, Carpenter PB, Elledge SJ, Science 2002 298 1435 1438 10.1126/science.1076182 12364621
70. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. DiTullio RA Jr, Mochan TA, Venere M, et al. Nat Cell Biol 2002 4 998 1002 10.1038/ncb892 12447382
71. Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response. Kao GD, McKenna WG, Guenther MG, Muschel RJ, Lazar MA, Yen TJ, J Cell Biol 2003 160 1017 1027 10.1083/jcb.200209065 12668657
72. Radiation response of mammalian cells grown in culture I. Repair of x-ray damage in surviving Chinese hamster cells. Elkind M, Sutton H, Radiation Res 1960 13 556 10.2307/3570945 13726391
73. Radiation response of mammalian tumor cells I. Repair of sublethal damage in vivo. Belli JA, Dicus GJ, Bonte FJ, J Natl Cancer Inst 1967 38 673 682 6025764
74. Apoptosis, oncosis, and necrosis. An overview of cell death. Majno G, Joris I, Am J Pathol 1995 146 3 15 7856735
75. Cell cycle regulation and radiation-induced cell death. Favaudon V, Cancer Radiother 2000 4 355 368 10.1016/S1278-3218(00)00009-3 11098223
76. Delayed reproductive death as a dominant phenotype in cell clones surviving X-irradiation. Chang WP, Little JB, Carcinogenesis 1992 13 923 928 10.1093/carcin/13.6.923 1600612
77. Radiation response of mouse lymphoid and myeloid cell lines part III. Different signals can lead to apoptosis and may influence sensitivity to killing by DNA double-strand breakage. Radford IR, Murphy TK, Int J Radiat Biol 1994 65 229 239 10.1080/09553009414550261 7907120
78. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Pollack A, Cowen D, Troncoso P, Zagars GK, von Eschenbach AC, Meistrich ML, McDonnell T, Cancer 2003 97 7 1630 1638 10.1002/cncr.11230 12655519
79. Expression of Bcl-2, p53, and p21 in benign and malignant prostatic tissue before and after radiation therapy. Rakozy C, Grignon DJ, Sarkar FH, Sakr WA, Littrup P, Forman J, Mod Pathol 1998 11 9 892 899 9758370
80. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Rosser CJ, Reyes AO, Vakar-Lopez F, Levy LB, Kuban DA, Hoover DC, Lee AK, Pisters LL, Int J Radiat Oncol Biol Phys 2003 56 1 1 6 10.1016/S0360-3016(02) 04468-1 12694817
81. p53 Protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cheng L, Sebo TJ, Cheville JC, Pisansky TM, Slezak J, Bergstralh EJ, Pacelli A, Neumann RM, Zincke H, Bostwick DG, Cancer 1999 85 6 1293 1299 10.1002/(SICI)1097-0142(19990315)85:6<1293::AID-CNCR11>3.0.CO;2- O 10189134
82. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. Grossfeld GD, Olumi AF, Connolly JA, Chew K, Gibney J, Bhargava V, Waldman FM, Carroll PR, J Urol 1998 159 5 1437 1443 10.1097/00005392-199805000-00004 9554329
83. p53 And Bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Huang A, Gandour-Edwards R, Rosenthal SA, Siders DB, Deitch AD, White RW, Urology 1998 51 2 346 351 10.1016/S0090-4295(97)00636-5 9495727
84. p53 Immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. Prendergast NJ, Atkins MR, Schatte EC, Paulson DF, Walther PJ, J Urol 1996 155 5 1685 1692 10.1016/S0022-5347(01)66165-2 8627854
85. p53 Gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis. Rakozy C, Grignon DJ, Li Y, Gheiler E, Gururajanna B, Pontes JE, Sakr W, Wood DP Jr, Sarkar FH, Pathol Res Pract 1999 195 3 129 135 10.1016/S0344-0338(99)80024-7 10220791
86. Bcl-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. Scherr DS, Vaughan ED Jr, Wei J, Chung M, Felsen D, Allbright R, Knudsen BS, J Urol 1999 162 2 503
87. Live or let die: the cell's response to p53. Vousden KH, Lu X, Nat Rev Cancer 2002 2 594 604 10.1038/nrc864 12154352
88. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG, Do KA, Brisbay SM, Wang X, Hossan EA, Evans RB, Soto C, Jacobson MG, Parker K, Merritt JA, Steiner MS, Logothetis CJ, Clin Cancer Res 2004 10 8 2587 2593 I added a better reference here 10.1158/1078-0432.CCR-03- 0388 15102659
89. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Sasaki R, Shirakawa T, Zhang ZJ, Tamekane A, Matsumoto A, Sugimura K, Matsuo M, Kamidono S, Gotoh A, Int J Radiat Oncol Biol Phys 2001 51 5 1336 1345 10.1016/S0360-3016(01)01803-X 11728695
90. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation. Colletier PJ, Ashoori F, Cowen D, Meyn RE, Tofilon P, Meistrich ME, Pollack A, Int J Radiat Oncol Biol Phys 2000 48 5 1507 1512 10.1016/S0360-3016(00)01409-7 11121656
91. Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Cowen D, Salem N, Ashoori F, Meyn R, Meistrich ML, Roth JA, Pollack A, Clin Cancer Res 2000 6 11 4402 4408 11106260
92. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE, Clin Cancer Res 2011 17 17 5638 5648 10.1158/1078-0432.CCR-11-0650 21799033
93. Poly (ADP-ribose) polymerase (PARP-1) is not involved in DNA double strand break recovery. Noël G, Giocanti N, Fernet M, Mégnin-Chanet F, Favaudon V, BMC Cell Biol 2003 4 7 10.1186/1471-2121-4-7 12866953
94. Mu-calpain activation in β-lapachone-mediated apoptosis. Tagliarino C, Pink J, Reinicke K, Simmers S, Wuerzberger-Davis S, Boothman D, Cancer Biol Ther 2003 2 141 152 12750552
95. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation. Moretti L, Niermann K, Schleicher S, Giacalone NJ, Varki V, Kim KW, Kopsombut P, Jung DK, Lu B, Int J Radiat Oncol Biol Phys 2011 80 4 1189 1197 10.1016/j.ijrobp.2011.01.060 21514073
96. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Guan Z, Wang XR, Zhu XF, et al. Cancer Res 2007 67 10436 10444 10.1158/0008-5472.CAN-07-1379 17974987
97. Chemosensitization by antisense oligonucleotides targeting MDM2. Bianco R, Ciardiello F, Tortora G, Curr Cancer Drug Targets 2005 5 1 51 56 10.2174/1568009053332681 15720189
98. Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Zhang R, Wang H, Agrawal S, Curr Cancer Drug Targets 2005 5 1 43 49 10.2174/1568009053332663 15720188
99. Radiosensitization by Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in in Vitro and in Vivo Human Cancer Models. Zhang Z, Wang H, Prasad G, Li M, Yu D, Bonner JA, Agrawal S, Zhang R, Clin Cancer Res 2004 10 4 1263 1273 10.1158/1078-0432.CCR-0245-03 14977824
100. Regulation of Akt PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC PTEN. Davies MA, Koul D, Dhesi H, et al. Cancer Res 1999 59 2551 2556 10363971
101. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Tanaka M, Rosser CJ, Grossman HB, Cancer Detect Prev 2005 29 2 170 174 10.1016/j.cdp.2004.07.006 15829377
102. Adenoviral-mediated PTEN Transgene Expression Sensitizes Bcl-2-Expressing Prostate Cancer Cells to Radiation. Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, Grossman HB, McDonnell TJ, Kuban DA, Meyn RE, Cancer Gene Ther 2004 11 4 273 279 10.1038/sj.cgt.7700673 14765130
103. Bcl-2 Over-Expression Delays Radiation-Induced Apoptosis without Affecting the Clonogenic Survival of Human Prostate Cancer Cells. Kyprianou N, King ED, Bradbury D, Rhee JG, Int J Cancer 1997 70 3 341 348 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I 9033638
104. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. Lowe SL, Rubinchik S, Honda T, McDonnell TJ, Dong JY, Norris JS, Gene Ther 2001 8 18 1363 1371 10.1038/sj.gt.3301531 11571575
105. Par-4, a Pro-apoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Chendil D, Das A, Dey S, Mohiuddin M, Ahmed MM, Cancer Biol Ther 2002 1 2 152 160 12170775
106. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Anai S, Goodison S, Shiverick K, Iczkowski K, Tanaka M, Rosser CJ, Hum Gene Ther 2006 17 10 975 984 10.1089/hum.2006.17.975 16984224
107. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, Rosser CJ, Mol Cancer Ther 2007 6 1 101 111 10.1158/1535-7163.MCT-06-0367 17237270
108. A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity. Honda T, Kagawa S, Spurgers KB, Gjertsen BT, Roth JA, Fang B, Lowe SL, Norris JS, Meyn RE, McDonnell TJ, Cancer Biol Ther 2002 1 2 163 167 12170776
109. Enhancing Radiotherapy with Cyclooxygenase-2 Enzyme Inhibitors: a Rational advance? Choy H, Milas L, J Natl Cancer Inst 2003 95 19 1440 1452 10.1093/jnci/djg058 14519750
110. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Totzke G, Schulze-Osthoff K, Janicke RU, Oncogene 2003 22 39 8021 8030 10.1038/sj.onc.1206837 12970750
111. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS, J Biol Chem 2000 275 15 11397 11403 10.1074/jbc.275.15.11397 10753955
112. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells. Anai S, Tanaka M, Shiverick KT, Kim W, Takada S, Boehlein S, Goodison S, Mizokami A, Rosser CJ, J Urol 2007 177 5 1913 1917 10.1016/j.juro.2007.01.019 17437847
113. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Nakata E, Mason KA, Hunter N, Husain A, Raju U, Liao Z, Ang KK, Milas L, Int J Radiat Oncol Biol Phys 2004 58 369 375 10.1016/j.ijrobp.2003.09.061 14751505
114. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis. Milas L, Am J Clin Oncol 2003 26 4 66 S69 10.1097/00000421-200308002- 00006 12902859
115. COX-2 inhibitors as radiosensitizing agents for cancer therapy. Davis TW, Hunter N, Trifan OC, Milas L, Masferrer JL, Am J Clin Oncol 2003 26 4 58 S61 10.1097/00000421-200308002-00004 12902857
116. Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation. Fan Z, Chakravarty P, Alfieri A, Pandita TK, Vikram B, Guha C, Cancer Gene Ther 2000 7 10 1307 1314 10.1038/sj.cgt.0243 11059687
117. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P, Yu DC, Cancer Gene Ther 2005 12 8 715 722 15832172
118. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N, Lee J, Pennathur-Das R, Radzyminski J, Wypych J, Brignetti D, Scott S, Stephens J, Karpf DB, Henderson DR, Yu DC, Cancer Res 2001 61 14 5453 5460 11454691
119. Migration and invasion of human prostate cancer cells is related to expression of VEGF and its receptors. Qi L, Robinson WA, Brady BM, Glode LM, Anticancer Res 2003 23 5a 3917 3922 14666697
120. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas. Kaliberov SA, Kaliberova LN, Buchsbaum DJ, Gene Ther 2005 12 5 407 417 10.1038/sj.gt.3302432 15616600
121. Restoration of transforming growth factor beta signaling pathway in human prostate cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Guo Y, Kyprianou N, Cancer Res 1999 59 6 1366 1371 10096572
122. Caspase-1 enhances the apoptotic response of prostate cancer cells to ionizing radiation. Winter RN, Rhee JG, Kyprianou N, Anticancer Res 2004 24 3a 1377 1386 15274298
123. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM, Cancer Res 2002 62 2942 2950 12019176
124. Insulin and insulin-like growth factor signalling in neoplasia. Pollak M, Nat Rev Cancer 2008 8 915 928 10.1038/nrc2536 19029956
125. Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Rochester MA, Riedemann J, Hellawell GO, Brewster SF, Macaulay VM, Cancer Gene Ther 2005 12 90 100 10.1038/sj.cgt.7700775 15499378
126. Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks. Benjamin W, Turney, et al. Radiother Oncol 2012 103 402 409 10.1016/j.radonc.2012.03.009 22551565
127. The ADAM metalloproteinases. Edwards DR, Handsley MM, Pennington CJ, Mol Aspects Med 2008 29 5 258 289 10.1016/j.mam.2008.08.001 18762209
128. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Sung SY, Kubo H, Shigemura K, Arnold RS, Logani S, Wang R, Konaka H, Nakagawa M, Mousses S, Amin M, Anderson C, Johnstone P, Petros JA, Marshall FF, Zhau HE, Chung LW, Cancer Res 2006 66 19 9519 9526 10.1158/0008-5472.CAN-05- 4375 17018608
129. Critical function for ADAM9 in mouse prostate cancer. Peduto L, Reuter VE, Shaffer DR, Scher HI, Blobel CP, Cancer Res 2005 65 20 9312 9319 10.1158/0008-5472.CAN-05-1063 16230393
130. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Fritzsche FR, Jung M, Tolle A, Wild P, Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C, Calvano D, Grutzmann R, Jung K, Kristiansen G, Eur Urol 2008 54 5 1097 1106 10.1016/j.eururo.2007.11. 034 18061337
131. Inhibition of ADAM9 expression induces epithelial phenotypic alterations and sensitizes human prostate cancer cells to radiation and chemotherapy. Josson S, Anderson CS, Sung SY, Johnstone PA, Kubo H, Hsieh CL, Arnold R, Gururajan M, Yates C, Chung LW, Prostate 2011 71 3 232 240 10.1002/pros.21237 20672324
132. Didox (a novel ribonucleotide Reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3. Inayat MS, Chendil D, Mohiuddin M, Elford HL, Gallicchio VS, Ahmed MM, Cancer Biol Ther 2002 1 5 546 547 12496486
133. Farnesyltransferase Inhibitors as Radiation Sensitizers. McKenna WG, Muschel RJ, Gupta AK, Hahn SM, Bernhard EJ, Semin Radiat Oncol 2002 12 3 27 32 10.1053/srao.2002.34866 12174342
134. Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival. Shi Y, Wu J, Mick R, Cerniglia GJ, Cohen-Jonathan E, Rhim JS, Koch CJ, Bernhard EJ, Prostate 2005 62 1 69 82 10.1002/pros.20122 15389805
135. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM, J Clin Oncol 2005 23 17 3923 3931 10.1200/JCO.2005.14.167 15897550
136. Modulation of radiation response by histone deacetylase inhibition. Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM, Int J Radiat Oncol Biol Phys 2005 62 1 223 229 10.1016/j.ijrobp.2004.12.088 15850925
137. Neurotensin and growth of normal and neoplastic tissues. Evers BM, Peptides 2006 27 2424 2433 10.1016/j.peptides.2006.01.028 16904238
138. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Carraway RE, Plona AM, Peptides 2006 27 2445 2460 10.1016/j.peptides.2006.04.030 16887236
139. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Amorino GP, Deeble PD, Parsons SJ, Oncogene 2007 26 745 756 10.1038/sj.onc.1209814 16862179
140. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Swift SL, Burns JE, Maitland NJ, Cancer Res 2010 70 347 356 10.1158/0008-5472.CAN-09-1252 20048080
141. Involvement of MAP-kinase, PI3- kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells. Hassan S, Dobner PR, Carraway RE, Regul Pept 2004 120 155 166 10.1016/j.regpep.2004.03.004 15177934
142. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. Valerie NC, Casarez EV, Dasilva JO, Dunlap-Brown ME, Parsons SJ, Amorino GP, Dziegielewski J, Cancer Res 2011 71 21 6817 6826 10.1158/0008-5472.CAN-11-1646 21903767
143. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T, Wakabayashi K, Jpn J Clin Oncol 1998 28 360 363 10.1093/jjco/28.6. 360 9730149
144. Growth inhibition of prostate cell lines in vitro by phyto-oestrogens. Hempstock J, Kavanagh JP, George NJ, Br J Urol 1998 82 560 563 10.1046/j.1464-410X.1998.00769.x 9806188
145. Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity. Kyle E, Neckers L, Takimoto C, Curt G, Bergan R, Mol Pharmacol 1997 51 193 200 9203623
146. Genistein potentiates inhibition of tumor growth by radiation in a prostate cancer orthotopic model. Hillman GG, Wang Y, Kucuk O, Che M, Doerge DR, Yudelev M, Joiner MC, Marples B, Forman JD, Sarkar FH, Mol Cancer Ther 2004 3 10 1271 1279 15486194
147. Combination of genistein with ionizing radiation on androgen-independent prostate cancer cells. Yan SX, Ejima Y, Sasaki R, Zheng SS, Demizu Y, Soejima T, Sugimura K, Asian J Androl 2004 6 4 285 290 15546018
148. Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Rashid A, Liu C, Sanli T, Tsiani E, Singh G, Bristow RG, Dayes I, Lukka H, Wright J, Tsakiridis T, Radiat Oncol 2011 6 144 10.1186/1748-717X-6-144 22029423
149. Role of DAB2IP in modulating epithelialto- mesenchymal transition and prostate cancer metastasis. Xie D, Gore C, Liu J, et al. Proc Natl Acad Sci USA 2010 107 2485 2490 10.1073/pnas.0908133107 20080667
150. Downregulation of human DAB2IP gene expression in prostate cancer cells results in resistance to ionizing radiation. Kong Z, Xie D, Boike T, Raghavan P, Burma S, Chen DJ, Habib AA, Chakraborty A, Hsieh JT, Saha D, Cancer Res 2010 70 7 2829 2839 Epub 2010 Mar 23 10.1158/0008-5472.CAN-09-2919 20332235
151. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Chen H, Pong RC, Wang Z, Hsieh JT, Genomics 2002 79 573 581 10.1006/geno.2002.6739 11944990
152. Death and antideath: tumour resistance to apoptosis. Igney FH, Krammer PH, Nat Rev Cancer 2002 2 277 288 10.1038/nrc776 12001989
153. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Oliver CL, Miranda MB, Shangary S, Land S, Wang S, Johnson DE, Mol Cancer Ther 2005 4 1 23 31 15657350
154. Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J, Al-Katib A, Mol Cancer Ther 2005 4 1 13 21 10.1186/1476-4598-4-13 15657349
155. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Xu L, Yang D, Wang S, Tang W, Liu M, Davis M, Chen J, Rae JM, Lawrence T, Lippman ME, Mol Cancer Ther 2005 4 2 197 205 10.4161/cbt.4.2.1441 15713891
156. Synthesis and biological evaluation of aromatic enones related to curcumin. Robinson TP, Hubbard RB 4th, Ehlers TJ, Arbiser JL, Goldsmith DJ, Bowen JP, Bioorg Med Chem 2005 13 12 4007 4013 10.1016/j.bmc.2005.03.054 15911313
157. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Notarbartolo M, Poma P, Perri D, Dusonchet L, Cervello M, D'Alessandro N, Cancer Lett 2005 224 1 53 65 10.1016/j.canlet.2004.10.051 15911101
158. Therapeutic potential of curcumin in human prostate cancer-I. Curcumin induces apoptosis in both androgen-dependent and androgen-independent prostate cancer cells. Dorai T, Gehani N, Katz A, Prostate Cancer Prostatic Dis 2000 3 2 84 93 10.1038/sj.pcan.4500399 12497104
159. Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Chendil D, Ranga RS, Meigooni D, Sathishkumar S, Ahmed MM, Oncogene 2004 26;23 8 1599 1607 23416982
160. Natural IAP inhibitor Embelin enhances therapeutic efficacy of ionizing radiation in prostate cancer. Yao D, et al. Am J Cancer Res 2011 1 2 128 143 21804946
161. Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells. Jiang C, Hu H, Malewicz B, Wang Z, Lu J, Mol Cancer Ther 2004 3 7 877 884 15252149
162. Redox modulation of human prostate carcinoma cells by Selenite increases radiation-induced cell killing. Husbeck B, Peehl DM, Knox SJ, Free Radic Biol Med 2005 38 1 50 57 10.1016/j.freeradbiomed.2004.09.022 15589371
163. A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Sun Y, St Clair DK, Xu Y, Crooks PA, St Clair WH, Cancer Res 2010 70 2880 2890 10.1158/0008-5472.CAN-09-4572 20233868
164. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Milosevic M, Warde P, Ménard C, Chung P, Toi A, Ishkanian A, McLean M, Pintilie M, Sykes J, Gospodarowicz M, Catton C, Hill RP, Bristow R, Clin Cancer Res 2012 18 2108 2114 10.1158/1078-0432.CCR-11-2711 22465832
165. Intrinsic markers of tumour hypoxia and angiogenesis in localized prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, et al. Lancet Oncol 2008 9 342 351 10.1016/S1470-2045(08)70076-7 18343725
166. A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. Joensuu G, Joensuu T, Nokisalmi P, et al. Int J Radiat Oncol Biol Phys 2010 78 1 42 49 10.1016/j.ijrobp.2009.07. 1731 20004525
167. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer. Vuky J, Pham HT, Warren S, et al. Int J Radiat Oncol Biol Phys 2012 82 4 609 e615 Epub 2011 Dec 28 10.1016/j.ijrobp.2011.09.002 22208976
168. Soy isoflavones in conjunction with radiation therapy in patients with prostate cancer. Ahmad IU, Forman JD, Sarkar FH, et al. Nutr Cancer 2010 62 7 996 1000 10.1080/01635581.2010.509839 20924975
169. Activation of programmed cell death in rat ventral prostate following castration. Kyprianou N, Saacs JT, Endocrinology 1988 22 552 562
170. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L, Lancet Oncol 2010 11 11 1066 1073 Epub 2010 Oct 7 10.1016/S1470-2045(10)70223-0 20933466
171. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU, Radiation Therapy Oncology Group, J Clin Oncol 2003 21 3 972 978